No Data
HK stocks jumped | CSPC Pharma-B (02616) rose more than 4% as the European Commission approved the use of sintilimab for first-line treatment of non-small cell lung cancer.
Biostone Pharmaceutical - B (02616) rose more than 4%, as of the time of publication, up 4.17%, reporting HKD 1.25, with a turnover of 0.941 million Hong Kong dollars.
Chi-Med-B (02616) rose 4.17%. Sintilimab, the domestically produced PD-L1 monoclonal antibody, has entered the international market after receiving approval from the European Union.
Kinwox Financial News | The stock price of Foundation Medicine Group B(02616) rose at the beginning of trading. As of press time, it increased by 4.17%, reporting at HKD 1.25, with a turnover of 9.285 million HKD. The company recently announced that the European Commission (EC) has approved the use of cegritide (trade name: Cejemly) in combination with platinum-based chemotherapy for first-line treatment of adult patients with metastatic non-small-cell lung cancer (NSCLC) with no EGFR sensitive mutations, or no ALK, ROS1, RET genomic tumor variations. Cegritide has become the first worldwide drug launching in Europe for first-line treatment of squamous and nonsquamous lung cancer in combination with chemotherapy.
Express News | CStone Pharmaceuticals - Actively Preparing to Submit Additional MAAS to EMA for New Indications, Including Stage III Nsclc
AstraZeneca Pharma (China) - B (02616.HK): Cejemly has been approved by the European Commission for first-line treatment of non-small cell lung cancer.
On July 26th, GalenPharma announced that the European Commission (EC) has approved the use of the drug, Cejemly, a PD-L1 inhibitor, in combination with platinum-based chemotherapy as a first-line treatment for adult patients with metastatic non-small cell lung cancer (NSCLC) who do not have EGFR sensitive mutations, or ALK, ROS1, RET gene alterations. Cejemly is the first PD-L1 inhibitor to be marketed in Europe for first-line treatment of squamous and non-squamous NSCLC in combination with chemotherapy, and GalenPharma is also the first company to bring domestically produced PD-L1 antibodies to the international market as an innovative product.
Express News | CStone Pharmaceuticals - European Commission Approval of Sugemalimab (Cejemly) as First-Line Treatment for Non-Small Cell Lung Cancer
CStone Pharmaceuticals Grants Exclusive Promotion Rights for Tumor Drug in China to Jiangsu Hengrui Medicine
CStone Pharmaceuticals (HKG:2616) Not Doing Enough For Some Investors As Its Shares Slump 34%
No Data
